How to Save on Your Prescriptions

The approvals of tafamidis (Vyndamax) and tafamidis meglumine (Vyndaqel) in 2019 were a victory for patients with transthyretin-mediated amyloidosis cardiomyopathy (ATTR-CM). These new agents...